Startseite>>Signaling Pathways>> Proteases>> ACE>>Leucylarginylproline

Leucylarginylproline

Katalog-Nr.GC32520

Leucyarginylprolin ist ein Angiotensin-Converting-Enzym (ACE)-Hemmer mit einem IC50-Wert von 0,27 μM.

Products are for research use only. Not for human use. We do not sell to patients.

Leucylarginylproline Chemische Struktur

Cas No.: 133943-59-6

Größe Preis Lagerbestand Menge
1mg
82,00 $
Auf Lager
5mg
331,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Leucylarginylproline is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 0.27μM.

Intravenous injection of Leucylarginylproline (30mg/kg) causes a decrease in the blood pressure. The maximum mean blood pressure reduction (about 15 mmHg) occurrs about 2 min after the injection[1]. Leucylarginylproline peptide reduces the blood pressure by about 15 mmHg at the fourth hour and shows a maximal reduction effect of about 35 mmHg at the eighth hour after oral administration[2].

[1]. Miyoshi S, et al. Structures and activity of angiotensin-converting enzyme inhibitors in an alpha-zein hydrolysate. Agric Biol Chem. 1991 May;55(5):1313-8. [2]. Chen TL, et al. Microencapsulation and modification of synthetic peptides of food proteins reduces the blood pressure of spontaneously hypertensive rats. J Agric Food Chem. 2003 Mar 12;51(6):1671-5.

Bewertungen

Review for Leucylarginylproline

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Leucylarginylproline

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.